Hereditary deficiency of factor VIII (FVIII) leads to hemophilia A, a severe X-linked bleeding disorder. Current therapies include fixed-dose FVIII prophylaxis, factor replacement therapy, and most recently, gene therapy. Prophylaxis and FVIII replacement therapies are limited by incomplete efficacy, high cost, restricted availability, and development of neutralizing antibodies in chronically ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 12 (2): 1511-1521 (2013) J.J. Wang et al. treated individuals. Limited success has been obtained in preclinical trials using gene therapy for the treatment of hemophilia. Therefore, new options for therapy for hemophilia A are needed. We evaluated the potential of embryonic stem cells for correcting hemophilia A in mice. FVIII-deficient mouse blastocysts were collected and injected with mouse embryonic stem cells stably expressing green-fluorescent protein (GFP) and transferred to pseudopregnant recipient mice. Expression of FVIII was measured in the liver and plasma of the 5 chimeric mice that were produced. Three of these mice were GFPpositive at the age of 6 months. The plasma FVIII activity levels were equal to those of wild-type mice. These data demonstrate that embryonic stem cell transplantation at an early embryonic stage has potential as therapy for this progressively debilitating, lifethreatening bleeding disorder.
INTRODUCTION
Hemophilia A is a severe inherited X-linked bleeding disorder caused by quantitative or qualitative deficiency of coagulation factor VIII (FVIII). Hemophilia A occurs in 1-2 individuals per 10,000 and represents roughly 90% of hemophilia cases (Fakharzadeh et al., 2000; Xu et al., 2009) . Clinically, the disease is characterized by spontaneous bleeding into the large joints and soft tissues. Recurrent episodes of joint bleeding are the most frequent symptom of the disease, leading to crippling arthropathy, particularly in severely affected patients. Currently, the most widely accepted treatment for hemorrhagic episodes is intravenous (iv) administration of plasma-derived FVIII concentrates or the recombinant FVIII protein. However, the high cost and unpredictable shortages of recombinant FVIII and risk of transmission of blood-borne viruses (historically, hepatitis A, B, and C, HIV, and B19 parvovirus) with plasma-derived FVIII have propelled researchers to look for alternative approaches (Moayeri et al., 2005) . Gene therapy of hemophilia has been initiated through a number of approaches including expression in muscle-, liver-, and omental-implanted fibroblasts, or iv injection of an expression vector under the control of a ubiquitous promoter (Montgomery et al., 2010) .
Limited success has been reported in preclinical trials using gene therapy for the treatment of hemophilia (Balague et al., 2000; Guo et al., 2001; Kootstra et al., 2003; Saenko et al., 2003; Tiede et al., 2003; Ye et al., 2004; Moayeri et al., 2005; Hauck et al., 2006; Ide et al., 2007; Matsui et al., 2007; Xu et al., 2005 Xu et al., , 2007 . Treatment failure is primarily caused by host immune responses to virally encoded proteins and lack of sustained production of the therapeutic gene products.
Embryonic stem (ES) cells can differentiate into most cell types, thus leading to intense interest in their potential for therapeutic applications (Hwang et al., 2004) . Our intent in this study was to evaluate the therapeutic application of ES cells for treatment of a preclinical mouse model of hemophilia A. Our results showed total correction of hemophilia A mice by in vivo ES cell therapy.
MATERIAL AND METHODS

Mice
FVIII-deficient (FVIII null ) mice have been previously described (Kuang et al., 2010) . Briefly, exons 16-19 of FVIII were deleted. Polymerase chain reaction (PCR), reverse-transcription (RT)-PCR, and immunohistochemistry confirmed FVIII deficiency in the FVIII gene knockout mouse. FVIII activity of FVIII null mice was remarkably lower than in normal mice. Since, the FVIII null mouse has significant, and even lethal, bleeding after trauma of tail snip, its phenotype appears grossly similar to that of humans with severe hemophilia A. The mutant mice were kept on an inbred 129S3 background under specific pathogen-free conditions. The protocols used in this study were approved by the Animal Use and Care Committee of Shanghai Jiao Tong University School of Medicine.
Cell culture
ES cells (from strain 129S3 mice) and stable green-fluorescent protein (GFP)-ES cell lines (transfected with pEGFP-N2) were grown and maintained undifferentiated at 37°C in 5% CO 2 on mitomycin C-treated mouse embryonic fibroblast feeder cells. ES and GFP-ES cells were cultured in KO-DMEM medium (Invitrogen, Carlsbad, CA, USA) plus 15% ES cell-grade FBS (Invitrogen), 0.1 mM non-essential amino acids, 2 mM L-glutamine, 0.1 mM 2-mercaptoethanol, 50 U/mL penicillin, 50 μg/mL streptomycin, 1 mM sodium pyruvate, and 1000 U/mL leukemia-inhibitory factor (Invitrogen).
Production of chimeric mice and experimental groups
Female FVIII null mice were superovulated with pregnant mare serum gonadotrophin and human chorionic gonadotrophin and mated to FVIII null male mice. In total, 65 blastocysts were isolated at day 3.5 postcoitum from females with a vaginal plug. The collected blastocysts were randomly divided into 2 groups: treatment group -35 blastocysts were injected with GFP-ES cells and transferred to pseudopregnant recipient females; control group -30 blastocysts were directly transferred to pseudopregnant recipient females. The pups were checked under a fluorescence-dissecting microscope for GFP expression 3 days after birth. Three of 5 pups derived from the injected blastocysts were GFP-positive. Four pups were born in the control group.
PCR analysis
Genomic DNA was extracted from the livers of chimeras and control mice at the age of 6 months. The FVIII and GFP genomic sequences were detected by using the following primers: FVIII: 5ꞌ-CACTTGTAAGAGTTTGGGGATG-3ꞌ (forward) and 5ꞌ-GTAATCTGGAAATCAC GGATGC-3ꞌ (reverse); GFP: 5'-CTGGTCGAGCTGGACGGCGACG-3' (forward) and 5'-CACGAACTCCAGCAGGACCATG-3' (reverse), respectively. All samples were also amplified to detect β-actin (forward primer: 5ꞌ-TACCCAGGCATTGCTGACAGG-3ꞌ; reverse primer: 5ꞌ-ACTTGCGGTGCACGATGGA-3ꞌ) as a control for the presence of amplifiable DNA. PCR products were analyzed by agarose gel electrophoresis and ethidium bromide staining.
RNA extraction and RT-PCR
Total RNA was extracted from cultured ES cells or mouse tissues with Trizol reagent (Invitrogen). Total RNA (2 μg) was reverse-transcribed, and PCR was done with ExTaq (Takara, Dalian, China). The primers used in this study are listed in Table 1 .
Gene symbol
Primer sequence (5ꞌ→3ꞌ) 
Alkaline phosphatase (ALP) staining
ES and GFP-ES cells were stained for ALP activity according to manufacturer instructions using the Alkaline Phosphatase Detection kit (Millipore, Billerica, MA, USA).
Factor VIII activity
A volume of 500 μL citrated test plasma was sent to Ruijin Hospital (Shanghai, China) for detection of FVIII activity using the chromogenic FVIII activity assay according to manufacturer instructions. A standard curve was created by using serial dilutions of normal human reference plasma. For plasma isolation, mice were anesthetized with ketamine/xylazine, and 1 mL blood was obtained by removing the eyeball and collected in 0.16 M sodium citrate at a final ratio of 1:10 (anticoagulant/blood).
Immunohistochemistry
Livers were removed and frozen in Tissue-Tek OCT compound (Sakura Finetechnical, Tokyo, Japan), and sections were cut at 8 μm thickness. Sections were air-dried for 30 min and fixed in 4% paraformaldehyde for 10 min. For staining, sections were covered with 1:100 anti-FVIII antibody (Santa Cruz, Santa Cruz, CA, USA) solution and incubated overnight at 4°C. After washing, the sections were incubated with goat anti-rabbit antibody (KPL, Gaith-ersburg, MD, USA) for 1 h at 37°C. After another wash, the sections were developed using the ABC kit (Vector Labs, Burlingame, CA, USA). The slides were then mounted in DPX (Sigma, St. Louis, MO, USA) and examined under a microscope with a 40X objective.
Statistical analysis
The results are reported as means ± standard error. The Student t-test was used for comparisons between groups. P less than 0.05 was considered to be statistically significant.
RESULTS
Characterization of GFP-ES cells
To confirm that the undifferentiated status of GFP-ES cells had not changed during the process of generating stable cell lines, we first examined the morphology and ALP activity of GFP-ES cells. It was found that GFP-ES cells were morphologically similar to ES cells including a round shape, large nucleoli, and scant cytoplasm ( Figure 1A) . Both ES and GFP-ES cell clones stained positive for ALP ( Figure 1B) . We further characterized GFP-ES cells at the molecular level by examining the expression of ES cell-specific markers. RT-PCR analyses showed that they expressed ES cell markers, including Nanog, Eras, Dax1, Oct3/4, Cripto, Fgf4, and Sox2, in quantities similar to those in ES cells ( Figure 1C ). 
A C B GFP expression in chimeric mice
We obtained 65 blastocysts from female FVIII null mice, and they were randomly divided into 2 parts: 35 of them were injected with GFP-ES cells and then implanted into 3 pseudopregnant recipient females; the remaining blastocysts were directly implanted into 3 pseudopregnant recipient females. After 18 days, 5 chimeric mice and 4 FVIII null mice were born. We used a fluorescence dissecting microscope to check whether GFP was expressed in pups 3 days after birth. GFP was easily visualized in 3 chimeric mice (chimeras gfp+ ), but not visualized in the other 2 chimeric mice (chimeras gfp-) ( Figure 2 ). 
FVIII expression in chimeric mice
The chimeric mice were viable and reached the adult stage without any gross morphological abnormalities. Six months later, the presence of FVIII and GFP sequences
A B C D
was demonstrated by genomic PCR in 3 of 5 chimeric livers ( Figure 3A) . Similarly, RT-PCR analyses showed that both FVIII and GFP were expressed in 3 of 5 chimeric livers. As the controls, FVIII mRNA from wide-type (1023 bp) and targeted alleles (284 bp) were detected in wide-type mice, and all chimeras and FVIII null controls, respectively ( Figure 3B ). All groups of mice were tested for FVIII activity. It was observed that the plasma FVIII:C levels in chimeras gfp+ were similar to those in wild-type control mice, but remarkably higher than those in FVIII null mice. The plasma FVIII:C levels in chimeras gfpwere not significantly different from those in FVIII null mice (Figure 4) .
Finally, we examined the expression and distribution of FVIII in the livers by immunohistochemical staining. The results showed that the FVIII protein was detectable in the chimeras gfp+ but not in FVIII null livers, and FVIII expression was noted in hepatocytes ( Figure 5) . These data reveal that ES cells transplanted into mouse embryos differentiated to FVIII-producing hepatocytes, leading to complete correction of the hemophilia A mouse phenotype. 
DISCUSSION
Hemophilia A is a rare X-linked bleeding disorder caused by the lack or dysfunction of coagulation FVIII (Yatuv et al., 2010) . Replacement therapy may be supplied on-demand (to stop a bleed) or prophylactically (to prevent bleeds). When treatment is provided on-demand, injections must be initiated at the first onset of symptoms so as to restrict both the amount of bleeding and the extent of the resulting tissue damage. Prophylactic therapy has been shown to provide hemophilia patients with better full-scale care than on-demand treatment, as it reduces the frequency of hemorrhages and retards the development of long-term arthropathy (Hoots and Nugent, 2006) . However, prophylactic treatment is more expensive than on-demand treatment and is not suitable for many patients. With either approach, neutralizing antibodies to the replacement protein have been reported, presenting a unique problem when treating hemophilia patients (Kaufman, 1999; Scandella, 2000) .
Gene therapy has long been recognized as a desirable treatment for hemophilia A, since it is caused by mutations in a single verified gene, and because a slight increase in clotting factor levels in vivo can convert severe hemophilia into a milder disease (Kessler, 2005) . However, all clinical trials for gene therapy in hemophilia A have been interrupted because of complications and failure to achieve significant FVIII expression in humans with hemophilia A (Pierce et al., 2007) .
A chimera is an animal that contains at least 2 different populations of genetically distinct cells. Chimeras are representatively seen in non-human zoology, but are also discovered to a rare extent in humans. Chimeric mice are vital tools in biological research, as they allow the study of a variety of biological questions in an animal that has 2 distinct genetic pools within it, which include insights into such problems as the tissue specific requirements of a gene, and cell lineage. The general methods for generating chimeric mice can be summarized as involving either injection or the aggregation of embryonic cells from different origins. The first chimeric mouse was created by Beatrice Mintz in the 1960s through the aggregation of 8-cell stage embryos (Mintz and Silvers, 1967) . Injection on the other hand was pioneered by Richard Gardner and Ralph Brinster who injected cells into blastocysts to generate chimeric mice with germ lines completely derived from injected ES cells (Robertson et al., 1983) . ES cells are also an important tool in chimeras because genes can be mutated in them through the use of homologous recombination, thus allowing gene targeting. Since this discovery took place in 1999, ES cells have become a key tool in the generation of specific chimeric mice (Doetschman et al., 1988 ).
In the current study, the chimeric mice described as chimeras gfp+ have 3 features that make them highly promising in the future. First, chimeras gfp+ are made through injection of the GFP-ES cells into the diploid embryo. Second, chimeras gfp+ are phenotypic correction of bleeding disorder. Third, FVIII has a short half-life requiring continuous replacement, but the FVIII protein is stably expressed in chimeras gfp+ .
In this study, some questions require further investigation. For example, long-term follow-up throughout their lifetimes will be needed to determine whether downstream adverse effects will emerge in the mice, and other stem cells need to be found to substitute ES cell. Ideally, one would like to use induced pluripotent stem (iPS) cells from patient's somatic cells, and these iPS cells need some genetic modifications. To date, iPS cells appear to be indistinguishable from ES cells and thus provide tremendous therapeutic potential (Hanna et al., 2007; Lewitzky and Yamanaka, 2007; Okita et al., 2007; Takahashi et al., 2007; Yu et al., 2007; Park et al., 2008) . Our results open the way to further investigations aimed at extending cell therapy for hemophilia A.
We demonstrated that ES cell transplantation at an early embryonic stage could rescue the hemophilia A phenotype in mice. This strategy, especially by using iPS, may be a potential therapy in the future for this progressively debilitating, life-threatening bleeding disorder.
